References
- Feldmann M, Brennan FM, Maini RN. Rheumatoid arthritis. Cell 1996;85:307–10.
- Firestein GS. Evolving concepts of rheumatoid arthritis. Nature 2003;423:356–61.
- Druker BJ, Talpaz M, Resta DJ, Peng B, Buchdunger E, Fird JM, et al. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med 2001;344:1031–7.
- Demettri GD, von Mehren M, Blanke CD, Van den Abbeele AD, Eisenberg B, Roberts PJ, et al. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med 2002;347:472–80.
- Miyachi K, Ihara A, Hankins RW, Murai R, Maehiro S, Miyashita H. Efficacy of imatinib mesylate (5TI571) treatment for a patients with rheumatoid arthritis developing chronic myelogenous leuke-mia. Clin Ftheumatol 2003;22:329–32.
- Eklund KK, Joensuu H. Treatment of rheumatoid arthritis with imatinib mesylate: clinical improvement in three refractory cases. Ann Med 2003;35:362–7.
- Sandler C, Joutsiniemi S, Lindstedt KA, Juutilainen T, Kovanen PT, Eklund KK. Imatinib mesylate inhibits platelet derived growth factor stimulated proliferation of rheumatoid synovial fibroblasts Biochem Biophys Res Commun 2006;347:31–5.
- Kameda H, Ishigami H, Suzuki M, Abe T, Takeuchi T. Imatinib mesylate inhibits proliferation of rheumatoid synovial fibroblast-like cells and phosphorylation of Gab adapter proteins activated by platelet-derived growth factor. Clin Exp Immunol 2006;144: 335–41.
- Ando W, Hashimoto J, Nampei A, Tsuboi T, Tateishi K, Ono T, et al. Imatinib mesylate inhibits osteoclastogenesis and joint destruction in rats with collagen-induced arthritis (CIA). J Bone Miner Metab 2006;24:274–82.
- Nandakumar KS, Svensson L, Holmdahl R. Collagen type II-specific monoclonal antibody-induced arthritis in mice: description of the disease and the influence of age, sex, and genes. Am J Pathol 2003;163:1827–37.
- Nandakumar KS, Backlund J, Vestberg M, Holmdahl R. Collagen type II (CII)-specific antibodies induce arthritis in the absence of T or B cells but the arthritis progression is enhanced by CII-reactive T cells. Arthritis Res Ther 2004;6:R544–50.
- Wang J, Fathman JW, Lugo-Villarino G, Scimone L, von Andrian U, Dorfman DM, et al. Transcription factor T-beta regulates inflammatory arthritis through its function in dendritic cells. J Clin Invest 2006;116:414–21.
- Kagari, T, Doi H, Shimozato T. The importance of IL-113 and TNF-a, and the noninvolvement of IL-6, in the development of monoclonal antibody-induced arthritis. J Immunol 2002;169: 1459–66.
- Paniagua RT, Sharpe 0, Ho PP, Chan SM, Chang A, Higgins JP, et al. Selective tyrosine kinase inhibition by imatinib mesylate for the treatment of autoimmune arthritis. J Clin Invest 2006;116: 2633–42.
- Bucala R, Ftitchlin C, Winchester R, Cerami A. Constitutive pro-duction of inflammatory and mitogenic cytokines by rheumatoid synovial fibroblasts. J Exp Med 1991;173:569–74.
- Cheon H, et al. Platelet-derived growth factor-AA increases IL-13 and IL-8 expression and activates NF-IcB in rheumatoid fibroblast-like synoviocytes. Scand J Immunol 2004;60:1121–9.
- Kasama T, Shiozawa F, Kobayashi K, Yajima N, Hanyuda M, Takeuchi HT, et al. Vascular endothelial growth factor expression by activated synovial leukocytes in rheumatoid arthritis: critical involvement of the interaction with synovial fibroblasts. Arthritis Rheum 2001;44:2512–24.
- Butler DM, Leizer T, Hamilton JA. Stimulation of human synovial fibroblast DNA synthesis by platelet-derived growth factor and fibroblast growth factor. Differences to the activation by IL-1. J Immunol 1989;142: 3098–103.
- Fava RA, Olsen NJ, Spencer-Green G, Yeo KT, Yeo TK, Berse B, et al. Vascular permeability factor/endothelial growth factor (VPF/VEGF): accumulation and expression in human synovial fluids and rheumatoid synovial tissue. J Exp Med 1994;180:341–6.
- Luttun A, Tjwa M, Moons L, Wu Y, Angelillo-Scherrer A, Liao F, et al. Revascularization of ischemic tissues by PIGF treatment, and inhibition of tumor angiogenesis, arthritis, and atherosclerosis by anti-Fltl. Nat Med 2002;8:831–40.